Potassium Iodide
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Potassium Iodide: Nasal cavity disease
One-Sentence Summary
Potassium iodide was originally used for upper respiratory conditions such as allergic rhinitis, vasomotor rhinitis, pharyngitis, the common cold and nasopharyngitis. The TxGNN model predicts it may be effective for nasal cavity disease, but there are currently no registered clinical trials and only 4 publications, all case reports (3 veterinary, 1 human) describing fungal or fungus-like nasal infections.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this drug. Based on known information, potassium iodide is a long-established treatment for certain fungal and fungus-like infections, such as sporotrichosis and zygomycosis (including conidiobolomycosis). It has also historically been used as an expectorant in upper respiratory conditions.
The original indications are all upper airway and nasal conditions, so the prediction for nasal cavity disease comes from the TxGNN model (deep learning). The score may reflect similarities the model learned between related diseases, not biological evidence. The retrieved literature suggests a plausible antifungal or anti-inflammatory role, but only in infectious nasal disease (fungal rhinitis, rhinofacial pythiosis and nasofacial zygomycosis). It does not support nasal cavity disease broadly.
The very high TxGNN score is a model prediction only. No controlled human data corroborate it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34902797 | 2022 | Case report (veterinary, sheep) | Journal de mycologie medicale | Successful potassium iodide treatment of rhinofacial pythiosis (Pythium insidiosum) in sheep |
| 39576399 | 2024 | Case report (veterinary, horse) | Veterinary research communications | Mycotic rhinitis caused by Aspergillus fumigatus in a mare, treated with topical clotrimazole plus oral potassium iodide |
| 10976304 | 2000 | Case report (veterinary, horse) | Journal of the American Veterinary Medical Association | Pseudallescheria boydii infection of the nasal cavity in a horse, treated with intranasal miconazole and intravenous sodium iodide |
| 7997795 | 1994 | Case report (human) | Revista do Instituto de Medicina Tropical de Sao Paulo | Nasofacial zygomycosis in a 64-year-old woman from Brazil, with rapid response to potassium iodide |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 418B | Not available | Not available | Not available |
Safety Considerations
No label-based warnings or contraindications were available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Contraindications flagged in the knowledge graph (these are model-derived associations, not label text). They include:
- Thyroid: hypothyroidism, myxedema, congenital hypothyroidism
- Cardiovascular: hypertension, hypertensive disorder
- Renal and hepatic: kidney disease, liver disease, liver failure
- Respiratory: chronic obstructive pulmonary disease
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, inherited porphyria
- Gastrointestinal: peptic ulcer disease, inflammatory bowel disease, pancreatitis, gallbladder disease
- Neurological and psychiatric: epilepsy, psychotic disorders, anxiety disorder
- Other: thrombocytopenia, dermatitis herpetiformis
Drug interactions: 45 interactions were identified. The main ones from the listed entries are:
- Major:
- ACE inhibitors: benazepril, captopril, enalapril, lisinopril, moexipril, perindopril, quinapril
- Angiotensin receptor blockers: olmesartan, valsartan, azilsartan medoxomil, losartan, telmisartan
- Trimethoprim
- Moderate:
- NSAIDs: ketorolac, ibuprofen, diclofenac, oxaprozin, naproxen
- Aliskiren
- Tolvaptan
The major interactions with ACE inhibitors, ARBs and trimethoprim are most likely related to hyperkalaemia risk, since this is a potassium salt. This is an inference and should be confirmed in the PI.
Iodides can also cause hypersensitivity reactions and iodism, which should be considered in any new use.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a high model score and four case reports in infectious nasal disease, with no registered trials or controlled human data. The evidence does not support nasal cavity disease broadly. It is best treated as a research question, narrowed to fungal or fungus-like nasal infections.
To proceed, the following is needed:
- Mechanism of action data
- TGA-approved Product Information, including approved indications, warnings and contraindications. The Australian licence record has no indication text, product name or dosage form.
- A narrower, well-defined indication (for example, fungal rhinosinusitis or conidiobolomycosis) with systematic review of human case data
- Controlled or prospective clinical data in humans
- A safety plan covering thyroid function, hyperkalaemia and hypersensitivity, particularly for patients taking ACE inhibitors, ARBs or trimethoprim
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.